Typenex Medical Logo
Toll Free: 866.897.3639

PIFA PlussPF4™

PIFA PlussPF4™ is a whole blood assay designed to detect or rule-out the presence of antibodies that are the major determinant in the development of Heparin-Induced Thrombocytopenia (HIT). Clinicians get real-time patient data for making time-sensitive anticoagulation decisions.

Sending tests to reference labs often leads to increased turn-around times that are measured in days and higher costs. While clinicians wait for results, patients suspected of having HIT may be taken off Heparin as a precaution and put on more expensive, alternative anticoagulants called Direct Thrombin Inhibitors (DTIs). Many individuals will ultimately test negative for HIT Antibodies and not have a Heparin allergy, but will be exposed to DTIs that are also more difficult to manage and may cause bleeding complications. Help clinicians have the most up-to-date patient information available, before changing therapies. Deliver HIT Antibody results quickly, save money, and avoid unnecessary work.

Information about PIFA PlussPF4™

Ruling out PF4 antibodies rapidly enables clinicians to avoid unnecessary heparin discontinuation and use of alternative anticoagulant therapies, such as Direct Thrombin Inhibitors (DTIs) that can result in:

  • Clinical monitoring requirements and associated costs
  • Increased length of stay (LOS)
  • Potential side effects
  • High drug therapy costs

Key Benefits of PIFA PlussPF4™

Ideal for labs of all sizes, PIFA PlussPF4™ offers several advantages:

  • Rule out Heparin/PF4 antibodies that are associated with HIT
  • Rapid results (<1 hour)
  • Dramatic cost savings potential
  • Incorporates first-in-class WHOLE BLOOD sample preparation with serastat™


Ordering Information

PIFA PlussPF4™ Devices (6 tests/pack) 4001101
PIFA PlussPF4™ - Controls, 2 Panel (1Pos/1Neg) 4000007
PIFA PlussPF4™ - Controls, 10 Panel (5Pos/5Neg) 4000006
Request a sample

Typenex Medical is a proud distributor of PIFA PlussPF4™.

PIFA PlussPF4™ is a trademark of Akers Biosciences, Inc.